Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JMP Securities analyst Reni Benjamin reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and maintains $3...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintain...
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $38 price target.
Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising ...
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $38 price target.
Cantor Fitzgerald analyst Li Watsek reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Overweight.
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safe...
RBC Capital analyst Gregory Renza initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform rating and anno...
